KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Net Interest Income

Last Annual Value

-1.44M

3-Year CAGR

-83%

5-Year CAGR

-16%

10-Year CAGR

-8%

KT

Kalaris Therapeutics Inc Competitors Analysis of Net Interest Income

KLRS · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-1.44M
N/AN/AN/A 
0.00
N/AN/AN/A
5.96M
33.0%N/AN/A
2.70M
-16.7%34.0%N/A
3.38M
42.6%N/AN/A
9.47M
-15.1%N/AN/A
0.00
N/AN/AN/A
2.36M
-36.2%N/AN/A
1.54M
6.9%N/AN/A
-90.00K
N/AN/AN/A
2.37M
-18.9%47.4%17.8%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7